CAS NO: | 1456607-71-8 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviralnon-structural protein 3/4A (NS3/4A) proteaseinhibitor with EC50s of 1 and 0.21 nM againstHCV1a and 1b, respectively. Paritaprevir dihydrate is also aSARS-CoV3CLproinhibitor with an IC50of 1.31 μM. Paritaprevir dihydrate is metabolized primarily bycytochrome P450(CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced byRitonavir(a CYP450 inhibitor)[1][2][3][4]. |
IC50& Target | EC50: 1 nM (HCV 1a), 0.21 nM (HCV 1b)[1] |
体外研究 (In Vitro) | Paritaprevir hasin vitroantiviral activity against HCV GT1-4 and GT6 (EC50range, 0.09 to 19 nM), with an EC50of 0.09 nM against GT4a[2]. |
体内研究 (In Vivo) | The combination of Paritaprevir,Ritonavir,Ombitasvir(an NS5A protein inhibitor), andDasabuvir(an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections[1][4]. |
Clinical Trial | |
分子量 | 801.91 |
Formula | C40H47N7O9S |
CAS 号 | 1456607-71-8 |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |